189 related articles for article (PubMed ID: 30929579)
1. CRRL269.
Chen Y; Harty GJ; Zheng Y; Iyer SR; Sugihara S; Sangaralingham SJ; Ichiki T; Grande JP; Lee HC; Wang X; Burnett JC
Circ Res; 2019 May; 124(10):1462-1472. PubMed ID: 30929579
[TBL] [Abstract][Full Text] [Related]
2. CRRL269: a novel designer and renal-enhancing pGC-A peptide activator.
Chen Y; Harty GJ; Huntley BK; Iyer SR; Heublein DM; Harders GE; Meems L; Pan S; Sangaralingham SJ; Ichiki T; Burnett JC
Am J Physiol Regul Integr Comp Physiol; 2018 Mar; 314(3):R407-R414. PubMed ID: 29187381
[TBL] [Abstract][Full Text] [Related]
3. Cenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing in vivo and ex vivo actions.
Lee CY; Huntley BK; McCormick DJ; Ichiki T; Sangaralingham SJ; Lisy O; Burnett JC
Eur Heart J Cardiovasc Pharmacother; 2016 Apr; 2(2):98-105. PubMed ID: 27340557
[TBL] [Abstract][Full Text] [Related]
4. A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension.
McKie PM; Cataliotti A; Boerrigter G; Chen HH; Sangaralingham SJ; Martin FL; Ichiki T; Burnett JC
Hypertension; 2010 Dec; 56(6):1152-9. PubMed ID: 20975033
[TBL] [Abstract][Full Text] [Related]
5. Particulate Guanylyl Cyclase A/cGMP Signaling Pathway in the Kidney: Physiologic and Therapeutic Indications.
Chen Y; Burnett JC
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29584705
[TBL] [Abstract][Full Text] [Related]
6. M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics.
McKie PM; Cataliotti A; Ichiki T; Sangaralingham SJ; Chen HH; Burnett JC
J Am Heart Assoc; 2014 Jan; 3(1):e000206. PubMed ID: 24385449
[TBL] [Abstract][Full Text] [Related]
7. Activation of myocardial and renal natriuretic peptides during acute intravascular volume overload in dogs: functional cardiorenal responses to receptor antagonism.
Borgeson DD; Stevens TL; Heublein DM; Matsuda Y; Burnett JC
Clin Sci (Lond); 1998 Aug; 95(2):195-202. PubMed ID: 9680502
[TBL] [Abstract][Full Text] [Related]
8. Attenuated renal excretory response to atrial natriuretic peptide in congestive heart failure in man.
Eiskjaer H; Bagger JP; Danielsen H; Jensen JD; Jespersen B; Thomsen K; Pedersen EB
Int J Cardiol; 1991 Oct; 33(1):61-74. PubMed ID: 1657800
[TBL] [Abstract][Full Text] [Related]
9. [Diuretic and renoprotective effects of natriuretic peptides].
Mukoyama M; Suganami T; Nakao K
Nihon Rinsho; 2004 Sep; 62 Suppl 9():69-75. PubMed ID: 15506340
[No Abstract] [Full Text] [Related]
10. Glucocorticoids improve renal responsiveness to atrial natriuretic peptide by up-regulating natriuretic peptide receptor-A expression in the renal inner medullary collecting duct in decompensated heart failure.
Liu C; Chen Y; Kang Y; Ni Z; Xiu H; Guan J; Liu K
J Pharmacol Exp Ther; 2011 Oct; 339(1):203-9. PubMed ID: 21737535
[TBL] [Abstract][Full Text] [Related]
11. TRV120027, a novel β-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure.
Boerrigter G; Soergel DG; Violin JD; Lark MW; Burnett JC
Circ Heart Fail; 2012 Sep; 5(5):627-34. PubMed ID: 22891045
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic actions of a new synthetic vasoactive and natriuretic peptide, dendroaspis natriuretic peptide, in experimental severe congestive heart failure.
Lisy O; Lainchbury JG; Leskinen H; Burnett JC
Hypertension; 2001 Apr; 37(4):1089-94. PubMed ID: 11304508
[TBL] [Abstract][Full Text] [Related]
13. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure.
Cataliotti A; Boerrigter G; Costello-Boerrigter LC; Schirger JA; Tsuruda T; Heublein DM; Chen HH; Malatino LS; Burnett JC
Circulation; 2004 Apr; 109(13):1680-5. PubMed ID: 15023890
[TBL] [Abstract][Full Text] [Related]
14. Effects of auriculin (atrial natriuretic factor) on blood pressure, renal function, and the renin-aldosterone system in dogs.
Maack T; Marion DN; Camargo MJ; Kleinert HD; Laragh JH; Vaughan ED; Atlas SA
Am J Med; 1984 Dec; 77(6):1069-75. PubMed ID: 6239544
[TBL] [Abstract][Full Text] [Related]
15. George E. Brown memorial lecture. Role of atrial peptides in body fluid homeostasis.
Ballermann BJ; Brenner BM
Circ Res; 1986 May; 58(5):619-30. PubMed ID: 3011307
[TBL] [Abstract][Full Text] [Related]
16. Long-term blood pressure lowering and cGMP-activating actions of the novel ANP analog MANP.
Chen Y; Schaefer JJ; Iyer SR; Harders GE; Pan S; Sangaralingham SJ; Chen HH; Redfield MM; Burnett JC
Am J Physiol Regul Integr Comp Physiol; 2020 Apr; 318(4):R669-R676. PubMed ID: 32022596
[TBL] [Abstract][Full Text] [Related]
17. Dose-response study of atrial natriuretic peptide bolus injection in healthy man.
Eiskjaer H; Pedersen EB
Eur J Clin Invest; 1993 Jan; 23(1):37-45. PubMed ID: 8383057
[TBL] [Abstract][Full Text] [Related]
18. Renal role of the endogenous natriuretic peptide system in acute congestive heart failure.
Stevens TL; Rasmussen TE; Wei CM; Kinoshita M; Matsuda Y; Burnett JC
J Card Fail; 1996 Jun; 2(2):119-25. PubMed ID: 8798113
[TBL] [Abstract][Full Text] [Related]
19. C-type natriuretic peptide-induced relaxation through cGMP-dependent protein kinase and SERCA activation is impaired in two kidney-one clip rat aorta.
Pernomian L; do Prado AF; Silva BR; de Paula TD; Grando MD; Bendhack LM
Life Sci; 2021 May; 272():119223. PubMed ID: 33610574
[TBL] [Abstract][Full Text] [Related]
20. C-type natriuretic peptide ameliorates ischemia/reperfusion-induced acute kidney injury by inhibiting apoptosis and oxidative stress in rats.
Jin X; Zhang Y; Li X; Zhang J; Xu D
Life Sci; 2014 Nov; 117(1):40-5. PubMed ID: 25283078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
